Randomized Study of Ibrutinib Versus Ibrutinib Plus Rituximab (i Versus iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)

Trial Profile

Randomized Study of Ibrutinib Versus Ibrutinib Plus Rituximab (i Versus iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms i versus iR
  • Most Recent Events

    • 12 Dec 2017 Primary endpoint (Progression-Free survival (PFS) Rate (Ib+R versus Ib)) has not been met, according to results presented at presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top